Peers: JNJ ALGN NVO TEVA PFE MRK CRL DHR ABT EXAS

| Held by: MGMT DFAX DFIC GUSA SHRT

Index	-	P/E	-	EPS (ttm)	-1.02	Insider Own	89.25%	Shs Outstand	354.21M	Perf Week	5.26%
Market Cap	6.59B	Forward P/E	17.20	EPS next Y	1.08	Insider Trans	0.01%	Shs Float	38.09M	Perf Month	10.25%
Enterprise Value	11.51B	PEG	0.43	EPS next Q	0.06	Inst Own	10.59%	Short Float	8.83%	Perf Quarter	23.42%
Income	-360.00M	P/S	1.29	EPS this Y	53.86%	Inst Trans	-0.82%	Short Ratio	8.98	Perf Half Y	28.01%
Sales	5.10B	P/B	1.02	EPS next Y	37.77%	ROA	-2.62%	Short Interest	3.36M	Perf YTD	8.90%
Book/sh	18.20	P/C	16.60	EPS next 5Y	39.78%	ROE	-5.57%	52W High	18.64 -0.23%	Perf Year	16.47%
Cash/sh	1.12	P/FCF	-	EPS past 3/5Y	- -	ROIC	-3.10%	52W Low	10.45 77.99%	Perf 3Y	1.47%
Dividend Est.	-	EV/EBITDA	18.90	Sales past 3/5Y	10.62% 8.38%	Gross Margin	54.75%	Volatility	2.97% 3.30%	Perf 5Y	-
Dividend TTM	-	EV/Sales	2.26	EPS Y/Y TTM	-12.96%	Oper. Margin	3.69%	ATR (14)	0.57	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.04	Sales Y/Y TTM	6.47%	Profit Margin	-7.06%	RSI (14)	71.45	Recom	2.50
Dividend Gr. 3/5Y	- -	Current Ratio	1.55	EPS Q/Q	-1825.88%	SMA20	8.10%	Beta	0.59	Target Price	18.65
Payout	-	Debt/Eq	0.81	Sales Q/Q	9.77%	SMA50	8.53%	Rel Volume	1.09	Prev Close	18.44
Employees	13000	LT Debt/Eq	0.80	Earnings	Feb 18 BMO	SMA200	24.54%	Avg Volume	374.74K	Price	18.60
IPO	May 06, 2022	Option/Short	Yes / Yes	EPS/Sales Surpr.	-9.91% 1.42%	Trades		Volume	406,950	Change	0.87%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-26	Downgrade	Evercore ISI	Outperform → In-line	$18
Dec-11-25	Upgrade	Citigroup	Neutral → Buy	$20
Dec-02-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$21
Oct-01-25	Initiated	Goldman	Neutral	$16
May-02-25	Reiterated	H.C. Wainwright	Buy	$20 → $15
Mar-28-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$24 → $15
Dec-11-24	Downgrade	Citigroup	Buy → Neutral	$24 → $22
Dec-02-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$19
Oct-15-24	Upgrade	Evercore ISI	In-line → Outperform	$19 → $25
Jul-10-24	Initiated	Raymond James	Outperform	$19
May-06-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$16 → $18
Jan-04-24	Downgrade	Evercore ISI	Outperform → In-line	$19 → $17
Dec-12-23	Initiated	Stifel	Hold	$16
Oct-03-23	Resumed	Evercore ISI	Outperform	$20
May-30-23	Resumed	Morgan Stanley	Equal-Weight	$20
Mar-09-23	Initiated	Needham	Hold
Dec-21-22	Initiated	Barclays	Equal Weight	$17
Sep-12-22	Initiated	H.C. Wainwright	Buy	$21
Jul-26-22	Initiated	RBC Capital Mkts	Outperform	$22
Jun-24-22	Initiated	Evercore ISI	Outperform	$21

Show Previous Ratings

Feb-25-26 12:36AM	5 Revealing Analyst Questions From Bausch + Lomb's Q4 Earnings Call (StockStory)
Feb-24-26 07:00AM	Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY (Business Wire)
Feb-19-26 12:00PM	Bausch + Lomb (BLCO) Upgraded to Buy: Here's What You Should Know (Zacks)
12:31AM	BLCO Q4 2025 Deep Dive: Dry Eye and Product Innovation Propel Growth, Margin Expansion in Focus (StockStory)
Feb-18-26 10:11PM	Bausch Health Cos Q4 Earnings Call Highlights (MarketBeat)
04:31PM	Loading…
04:31PM	Bausch + Lomb Corporation Q4 2025 Earnings Call Summary (Moby)
02:58PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research)
02:23PM	1st contact lens innovation since 1999 is coming: Bausch + Lomb CEO (Yahoo Finance Video)
02:00PM	Bausch & Lomb Corp (BLCO) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
01:25PM	Why Bausch + Lomb's CEO is tying paychecks to AI literacy (Yahoo Finance)
01:25PM	Why Bauch + Lomb's CEO is tying paychecks to AI literacy (Yahoo Finance)
09:36AM	Bausch + Lomb Q4 Earnings Call Highlights (MarketBeat)
09:30AM	Bausch + Lomb (BLCO) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:10AM	Bausch + Lomb (BLCO) Lags Q4 Earnings Estimates (Zacks)
07:37AM	Bausch + Lomb's (NYSE:BLCO) Q4 CY2025: Beats On Revenue (StockStory)
07:19AM	Loading…
07:19AM	Bausch + Lomb: Q4 Earnings Snapshot (Associated Press Finance)
06:58AM	Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance (Business Wire)
Feb-16-26 10:07PM	Bausch + Lomb (BLCO) Q4 Earnings: What To Expect (StockStory)
09:15AM	Ahead of Bausch + Lomb (BLCO) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)
Feb-12-26 08:50AM	Organon (OGN) Misses Q4 Earnings and Revenue Estimates (Zacks)
Feb-11-26 09:30AM	Bausch + Lomb CEO: Standing still is the new falling behind (Fortune)
Feb-09-26 11:02PM	3 Reasons to Sell BLCO and 1 Stock to Buy Instead (StockStory)
11:40AM	BLCO or DHR: Which Is the Better Value Stock Right Now? (Zacks)
Jan-29-26 11:34PM	1 Healthcare Stock to Research Further and 2 Facing Headwinds (StockStory)
Jan-23-26 11:40AM	BLCO vs. HQY: Which Stock Is the Better Value Option? (Zacks)
Jan-20-26 07:15AM	Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18 (Business Wire)
Jan-05-26 07:00AM	Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S. (Business Wire)
Jan-02-26 04:30PM	Bausch + Lomb Completes Refinancing of Outstanding Term B Loans (Business Wire)
Dec-23-25 07:30AM	Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-17-25 04:30PM	Bausch + Lomb Announces Two Board of Directors Appointments (Business Wire)
04:48PM	Loading…
Dec-12-25 04:48PM	Bausch + Lomb Announces Refinancing of Outstanding Term B Loans (Business Wire)
Dec-11-25 11:41AM	Why Bausch + Lomb (BLCO) Stock Is Trading Up Today (StockStory)
Dec-04-25 10:09PM	Wall Street Cautious on ?Bausch + Lomb Corporation (BLCO), Here's Why (Insider Monkey)
Dec-02-25 11:10AM	Why Bausch + Lomb (BLCO) Stock Is Up Today (StockStory)
Nov-18-25 04:30PM	Bausch + Lomb to Participate in Citi Global Healthcare Conference (Business Wire)
Nov-13-25 02:57PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research) -5.48%
08:55AM	NYSE Content Advisory: Pre-Market Update + TKO and Polymarket Announce Partnership (PR Newswire)
08:41AM	Bausch + Lomb CEO Brent Saunders on growth outlook: Biggest contributor will be in surgical (CNBC TV)
Nov-10-25 06:59AM	Bausch + Lomb Reports More Than 690,000 Pounds of Contacts Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE Recycling Program (Business Wire)
04:28AM	Medical Devices & Supplies - Specialty Stocks Q3 In Review: Bausch + Lomb (NYSE:BLCO) Vs Peers (StockStory)
Nov-05-25 12:35AM	5 Revealing Analyst Questions From Bausch + Lomb's Q3 Earnings Call (StockStory)
Nov-03-25 04:30PM	Bausch + Lomb to Hold Investor Day on Nov. 13 (Business Wire)
Oct-30-25 01:34AM	BLCO Q3 Deep Dive: Pharmaceuticals and Pipeline Drive Growth, Margin Initiatives Take Shape (StockStory)
Oct-29-25 03:47PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research)
09:30AM	Bausch + Lomb (BLCO) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:05AM	Bausch + Lomb (BLCO) Q3 Earnings Beat Estimates (Zacks)
07:23AM	Bausch + Lomb (NYSE:BLCO) Reports Q3 In Line With Expectations, Stock Soars (StockStory)
07:06AM	Bausch + Lomb: Q3 Earnings Snapshot (Associated Press Finance)
06:58AM	Bausch + Lomb Announces Third-Quarter 2025 Results (Business Wire)
Oct-28-25 09:26AM	Bausch & Lomb Corp (TSX:BLCO) Q3 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-27-25 11:12PM	Bausch + Lomb (BLCO) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Oct-20-25 06:44PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research)
11:36AM	Bausch + Lomb (BLCO) Stock Is Up, What You Need To Know (StockStory)
09:34AM	Stocks to Watch Monday: Amazon, Zions Bancorp, Kering (The Wall Street Journal)
07:41AM	Cooper Cos. Stock Rises as Report Says Activist Investor Takes Stake (Barrons.com)
07:25AM	Activist Jana Pushes Big Contact-Lens Combination of Cooper and Bausch + Lomb (The Wall Street Journal)
Oct-19-25 08:00PM	Activist Jana Takes Stake in Cooper, a Maker of Medical Devices (The Wall Street Journal)
Oct-17-25 12:24PM	3 Stocks Under $50 We Steer Clear Of (StockStory)
Oct-10-25 06:44PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research)
Oct-02-25 11:40AM	BLCO vs. DHR: Which Stock Should Value Investors Buy Now? (Zacks)
Oct-01-25 11:01AM	Goldman Sachs initiates ophthalmology coverage: Buy Glaukos, sell Cooper (Investing.com)
Sep-25-25 01:06PM	Bausch + Lomb, Enovis, and Haemonetics Shares Plummet, What You Need To Know (StockStory)
Sep-11-25 07:00AM	Bausch + Lomb Announces Publication of enVista Envy Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial (Business Wire)
Sep-09-25 07:00AM	Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA in Alleviating Discomfort in Symptomatic Contact Lens Wearers (Business Wire)
Sep-08-25 06:56PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research)
04:30PM	Bausch + Lomb (BLCO) Stock Trades Up, Here Is Why (StockStory)
07:00AM	Bausch + Lomb Launches ASANA Gas Permeable Lenses in the United States (Business Wire)
Sep-05-25 12:41AM	3 Healthcare Stocks Walking a Fine Line (StockStory)
Aug-22-25 02:25PM	Bausch + Lomb (BLCO) Stock Is Up, What You Need To Know (StockStory)
Aug-20-25 11:31PM	Medical Devices & Supplies - Specialty Stocks Q2 Highlights: Bausch + Lomb (NYSE:BLCO) (StockStory)
Aug-18-25 05:48PM	Icahn representations resign Bausch + Lomb board after agreement termination (Reuters)
05:01PM	Bausch + Lomb Announces Board Changes (Business Wire)
Aug-14-25 07:15AM	Bausch + Lomb to Participate in Upcoming Investor Conferences (Business Wire)
Aug-12-25 11:55PM	5 Revealing Analyst Questions From Bausch + Lomb's Q2 Earnings Call (StockStory)
11:48PM	BLCO Q2 Deep Dive: Product Launches Offset Margin Pressures, Management Highlights Pipeline Investments (StockStory)
Aug-07-25 12:38AM	1 Stock Under $50 to Target This Week and 2 We Ignore (StockStory)
Jul-30-25 03:05PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research) -6.42%
12:16PM	Why Bausch + Lomb (BLCO) Stock Is Down Today (StockStory)
09:30AM	Bausch + Lomb (BLCO) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
08:10AM	Bausch + Lomb (BLCO) Q2 Earnings and Revenues Surpass Estimates (Zacks)
07:34AM	Bausch + Lomb's (NYSE:BLCO) Q2 Sales Top Estimates, Full-Year Outlook Slightly Exceeds Expectations (StockStory)
07:04AM	Bausch + Lomb: Q2 Earnings Snapshot (Associated Press Finance)
06:57AM	Bausch + Lomb Announces Second-Quarter 2025 Results (Business Wire)
05:38AM	New Strong Sell Stocks for July 30th (Zacks)
Jul-29-25 09:27AM	Bausch & Lomb Corp (TSX:BLCO) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
07:00AM	Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY Preservative Free Redness Reliever Eye Drops (Business Wire)
Jul-28-25 11:09PM	Bausch + Lomb (BLCO) Q2 Earnings Report Preview: What To Look For (StockStory)
Jul-24-25 05:04AM	New Strong Sell Stocks for July 24th (Zacks)
Jul-23-25 10:00AM	Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-22-25 08:45AM	Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity (PR Newswire)
Jul-21-25 09:13AM	Ophthalmic Implants Market: Focused Insights (2025-2030) Featuring Alcon, Carl Zeiss, Bausch + Lomb, Johnson & Johnson and 20 Other Industry Leaders (GlobeNewswire)
Jul-20-25 11:31PM	Medical Devices & Supplies - Specialty Stocks Q1 In Review: Bausch + Lomb (NYSE:BLCO) Vs Peers (StockStory)
Jul-01-25 07:00AM	Bausch + Lomb Combines Patient Voices and New Survey Insights to Combat Persistent Misconceptions about Dry Eye (Business Wire)
Jun-30-25 06:58AM	Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13 (Business Wire)
Jun-26-25 04:30PM	Bausch + Lomb Announces Closing of Upsized 675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility (Business Wire)
Jun-25-25 07:42AM	The Top 5 Analyst Questions From Bausch + Lomb's Q1 Earnings Call (StockStory)
Jun-23-25 11:58AM	Barclays Cut Bausch & Lomb Target to $16, Keeping Rating Neutral in Early June (Insider Monkey)
Jun-18-25 04:30PM	Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering (Business Wire)
Jun-10-25 08:48AM	Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement (Business Wire) +5.01%
Jun-04-25 06:59AM	Bausch + Lomb Launches Blink Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the United States (Business Wire)

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
COLLIS STEVEN H	Director	Feb 23 '26	Buy	17.81	15,000	267,150	20,255	Feb 24 04:23 PM
ROBERTSON RUSSEL C	Director	Feb 20 '26	Buy	17.90	4,400	78,760	72,407	Feb 24 04:16 PM
Ling Karen	Director	Feb 19 '26	Buy	17.74	4,000	70,968	41,676	Feb 23 04:20 PM
SAUNDERS BRENT L	CEO and Chairman of the Board	May 22 '25	Buy	11.28	22,000	248,072	719,156	May 27 08:16 AM
VON ESCHENBACH ANDREW C.	Director	May 02 '25	Buy	11.76	1,695	19,925	41,748	May 06 04:30 PM

Open in Screener

COR

Cencora Inc

Feb 25 • 04:00PM ET

363.03

-1.35 -0.37 %

Healthcare • Medical Distribution • USA • NYSE

Peers: CAH MCK HSIC ACH PDCO DXCM BIO HCA LH

| Held by: VTI VOO VO IVV SPY VTV XLV IWP VOE VIG

Index	S&P 500	P/E	43.66	EPS (ttm)	8.31	Insider Own	0.40%	Shs Outstand	194.52M	Perf Week	0.78%
Market Cap	70.62B	Forward P/E	18.53	EPS next Y	19.60	Insider Trans	-8.56%	Shs Float	193.76M	Perf Month	2.12%
Enterprise Value	76.92B	PEG	1.71	EPS next Q	4.87	Inst Own	96.39%	Short Float	2.29%	Perf Quarter	-0.72%
Income	1.63B	P/S	0.22	EPS this Y	10.09%	Inst Trans	-3.96%	Short Ratio	3.39	Perf Half Y	25.92%
Sales	325.78B	P/B	37.00	EPS next Y	11.24%	ROA	2.20%	Short Interest	4.43M	Perf YTD	7.48%
Book/sh	9.81	P/C	39.05	EPS next 5Y	10.84%	ROE	152.25%	52W High	377.54 -3.84%	Perf Year	44.90%
Cash/sh	9.30	P/FCF	19.58	EPS past 3/5Y	-0.34% -	ROIC	17.13%	52W Low	244.97 48.19%	Perf 3Y	128.94%
Dividend Est.	2.40 (0.66%)	EV/EBITDA	15.70	Sales past 3/5Y	10.43% 11.09%	Gross Margin	3.28%	Volatility	1.57% 3.01%	Perf 5Y	252.97%
Dividend TTM	2.30 (0.63%)	EV/Sales	0.24	EPS Y/Y TTM	18.24%	Oper. Margin	1.18%	ATR (14)	9.16	Perf 10Y	314.42%
Dividend Ex-Date	Feb 13, 2026	Quick Ratio	0.51	Sales Y/Y TTM	7.45%	Profit Margin	0.50%	RSI (14)	54.91	Recom	1.58
Dividend Gr. 3/5Y	6.14% 5.79%	Current Ratio	0.92	EPS Q/Q	14.47%	SMA20	1.36%	Beta	0.69	Target Price	407.64
Payout	27.63%	Debt/Eq	4.15	Sales Q/Q	5.45%	SMA50	3.66%	Rel Volume	0.54	Prev Close	364.38
Employees	51000	LT Debt/Eq	3.97	Earnings	Feb 04 BMO	SMA200	13.65%	Avg Volume	1.31M	Price	363.03
IPO	Apr 04, 1995	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.77% -0.15%	Trades		Volume	707,755	Change	-0.37%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-26	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$400
Jan-22-26	Upgrade	Jefferies	Hold → Buy	$440
Dec-09-25	Initiated	Barclays	Overweight	$400
Jun-03-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$337
Dec-04-24	Resumed	Mizuho	Outperform	$280
Sep-18-24	Downgrade	BofA Securities	Buy → Neutral	$275 → $245
Feb-26-24	Initiated	Leerink Partners	Outperform	$261
Jan-03-24	Initiated	Barclays	Overweight	$242
Dec-14-23	Initiated	Wells Fargo	Equal Weight	$213
Mar-31-23	Initiated	Citigroup	Buy	$185
Jan-31-23	Resumed	Evercore ISI	Outperform	$185
Oct-11-22	Upgrade	BofA Securities	Neutral → Buy	$160 → $169
Aug-22-22	Resumed	Morgan Stanley	Equal-Weight
Jul-11-22	Downgrade	Evercore ISI	Outperform → In-line	$150
Jun-07-22	Upgrade	Deutsche Bank	Hold → Buy	$167 → $178
May-26-22	Upgrade	Barclays	Equal Weight → Overweight
Apr-12-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$178
Apr-01-22	Resumed	Credit Suisse	Outperform	$180
Feb-04-21	Upgrade	Evercore ISI	In-line → Outperform
Jan-06-21	Upgrade	BofA Securities	Underperform → Neutral

Show Previous Ratings

Feb-19-26 07:56AM	COR's MWI Animal Health to Merge With Covetrus in $3.5 Billion Deal (Zacks)
Feb-18-26 07:00AM	Covetrus and MWI Animal Health to Merge (Business Wire)
Feb-17-26 08:52AM	Is the Options Market Predicting a Spike in Cencora Stock? (Zacks)
Feb-13-26 04:15PM	Cencora Closes $3.0 Billion Senior Notes Offering (Business Wire)
03:51PM	Cencora, Azenta, The Pennant Group, LifeStance Health Group, and Gilead Sciences Shares Are Soaring, What You Need To Know (StockStory)
11:37PM	Loading…
Feb-11-26 11:37PM	1 Momentum Stock with Impressive Fundamentals and 2 We Question (StockStory)
12:36AM	5 Revealing Analyst Questions From Cencora's Q4 Earnings Call (StockStory)
Feb-10-26 05:15PM	Cencora Prices $500 Million 3.950% Senior Notes Due 2029, $500 Million 4.250% Senior Notes Due 2030, $500 Million 4.600% Senior Notes Due 2033, $1.0 Billion 4.900% Senior Notes Due 2036 and $500 Million 5.650% Senior Notes Due 2056 (Business Wire)
07:31AM	What Are Wall Street Analysts' Target Price for Cencora Stock? (Barchart)
Feb-06-26 09:28AM	Low Volatility ETFs to Watch Amid Major Tech Sell-Off Over AI Panic (Zacks)
Feb-05-26 03:31PM	Cencora (COR) Stock Trades Up, Here Is Why (StockStory) +6.72%
01:58PM	Analyst Report: Cardinal Health, Inc. (Morningstar Research)
12:48PM	Cardinal Health Stock Jumps After Earnings. Its CEO Explains What Went Right. (Barrons.com)
10:35AM	Analyst Report: McKesson Corporation (Morningstar Research)
01:13AM	Cencora Q1 Earnings Call Highlights (MarketBeat)
12:34AM	Loading…
12:34AM	COR Q4 Deep Dive: Specialty Expansion and OneOncology Drive Strategic Shifts (StockStory)
Feb-04-26 11:42PM	Analyst Report: McKesson Corporation (Morningstar Research) -8.79%
04:05PM	Cencora Inc (COR) Q1 2026 Earnings Call Highlights: Strong US Growth Amid International Challenges (GuruFocus.com)
01:44PM	Analyst Report: Cencora, Inc. (Morningstar Research)
11:59AM	Cencora Stock Down Despite Q1 Earnings Beat, Gross Margin Improves (Zacks)
11:32AM	Cencora Lifts 2026 Sales Outlook Despite Q1 Revenue Miss (Benzinga)
11:12AM	Rotation out of Tech Stocks Weighs on the Broader Market (Barchart)
10:04AM	Cencora (COR) Q1 2026 Earnings Call Transcript (Motley Fool)
10:03AM	Stocks Mixed on Sector Rotation out of Tech (Barchart)
09:30AM	Cencora (COR) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
07:40AM	Cencora (COR) Q1 Earnings Top Estimates (Zacks)
06:47AM	Cencora (NYSE:COR) Misses Q4 CY2025 Revenue Estimates (StockStory)
06:38AM	Cencora: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
06:30AM	Cencora Reports Fiscal 2026 First Quarter Results (Business Wire)
Feb-02-26 10:06PM	Cencora (COR) Reports Earnings Tomorrow: What To Expect (StockStory)
07:47AM	Loading…
Feb-01-26 07:47AM	January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week (Yahoo Finance)
Jan-31-26 09:36AM	Analysts Lift Ratings and Price Targets as Cencora, Inc. (COR)'s Growth Story Gains Momentum (Insider Monkey)
Jan-30-26 09:15AM	Exploring Analyst Estimates for Cencora (COR) Q1 Earnings, Beyond Revenue and EPS (Zacks)
Jan-29-26 09:35AM	First Solar downgraded, Fortinet upgraded: Wall Street's top analyst calls (The Fly)
08:33AM	Can Specialty and International Momentum Support Cencora's Q1 Results? (Zacks)
Jan-27-26 08:09PM	Analyst Report: Cencora, Inc. (Morningstar Research)
Jan-26-26 01:27PM	IBD Stock Of The Day: Why Cardinal Health's Momentum Is 'Special' And Not Over Yet (Investor's Business Daily)
Jan-25-26 04:46AM	Here Are the Top Four Blue-Chip Stocks To Buy in 2026, According to WarrenAI (Investing.com)
Jan-22-26 07:30AM	Cencora Elects Ellen Cooper to Its Board of Directors (Business Wire)
Jan-12-26 07:51AM	3 Medical Supplies Stocks That Beat the Market Despite Macro Headwinds (Zacks)
Jan-09-26 09:06AM	What to Expect From Cencora's Next Quarterly Earnings Report (Barchart)
Jan-08-26 08:40PM	Analyst Report: Cencora, Inc. (Morningstar Research)
09:40AM	Why Cencora (COR) is a Top Value Stock for the Long-Term (Zacks)
07:57AM	Here's Why You Should Retain Cencora Stock in Your Portfolio Now (Zacks)
Jan-07-26 09:45AM	Here's Why Cencora (COR) is a Strong Growth Stock (Zacks)
Jan-06-26 04:30PM	Cencora Announces Date and Time for First Quarter Fiscal 2026 Earnings Release (Business Wire)
Jan-05-26 01:44PM	McKesson Builds Earnings Momentum on Specialty and Automation (Zacks)
Dec-30-25 07:33AM	Reasons to Add Cooper Companies Stock to Your Portfolio Now (Zacks)
Dec-29-25 10:17AM	Take the Zacks Approach to Beat the Markets: Castle Biosciences, Hamilton Insurance & Monster Beverage in Focus (Zacks)
08:52AM	Here's Why You Should Retain Glaukos Stock in Your Portfolio Now (Zacks)
Dec-26-25 07:18AM	Reasons to Retain Baxter International Stock in Your Portfolio Now (Zacks)
Dec-24-25 10:36PM	Q3 Rundown: Cencora (NYSE:COR) Vs Other Health Insurance Providers Stocks (StockStory)
09:11AM	These 3 Medical Stocks Have Wall Street's Bullish Vote for 2026 (Zacks)
Dec-23-25 02:09PM	Here's Why You Should Retain Merit Medical Stock in Your Portfolio Now (Zacks)
09:35AM	Zacks.com featured highlights include NVIDIA, Ralph Lauren, Expedia and Cencora (Zacks)
Dec-22-25 10:40AM	4 Stocks Trading Near 52-Week High With More Upside Potential (Zacks)
Dec-19-25 02:14PM	Jim Cramer Says "I like Cencora A Lot" But Notes "Cardinal Health's Got Them All Beat" (Insider Monkey)
11:05AM	Cencora to Acquire OneOncology to Expand Community Oncology Solutions (Zacks)
Dec-18-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Dec-17-25 09:45AM	Why Cencora (COR) is a Top Growth Stock for the Long-Term (Zacks)
Dec-16-25 03:52AM	Cencora takes majority stake in cancer care platform OneOncology for $5B (Healthcare Dive)
Dec-15-25 08:01PM	Lightning Round: Sell BP, says Jim Cramer (CNBC TV)
02:50PM	Analyst Report: Cencora, Inc. (Morningstar Research)
09:06AM	Take the Zacks Approach to Beat the Markets: Liquidia, Western Digital & Johnson & Johnson in Focus (Zacks)
07:00AM	Cencora Accelerates OneOncology Acquisition, Extending Solutions Offering for Community Oncology (Business Wire)
Dec-10-25 08:59AM	Here's Why You Should Add Cencora Stock to Your Portfolio Now (Zacks)
Dec-09-25 09:40AM	Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-05-25 11:30AM	Why Is Cencora (COR) Down 6.3% Since Last Earnings Report? (Zacks)
Dec-03-25 03:26PM	Why Cencora (COR) Shares Are Trading Lower Today (StockStory)
02:59PM	JPMorgan Raises Cencora (COR) Price Target After Financial Model Update (Insider Monkey)
03:35AM	How Is Cencoras Stock Performance Compared to Other Medical Stocks? (Barchart)
Dec-02-25 12:00PM	Cencora (COR) Upgraded to Buy: Here's Why (Zacks)
09:40AM	Here's Why Cencora (COR) is a Strong Value Stock (Zacks)
Dec-01-25 09:45AM	Here's Why Cencora (COR) is a Strong Growth Stock (Zacks)
09:20AM	Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus (Zacks)
Nov-28-25 07:08AM	CVS Health Delivers MBR Improvement: Is More Progress in the Cards? (Zacks)
Nov-26-25 09:09AM	GEHC Stock Gains Post Latest Launch to Optimize Radiology Workflows (Zacks)
Nov-25-25 09:50AM	Here's Why Cencora (COR) is a Strong Momentum Stock (Zacks)
Nov-24-25 09:15AM	Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run? (Zacks)
Nov-21-25 09:40AM	Are Medical Stocks Lagging Cencora, Inc. (COR) This Year? (Zacks)
Nov-18-25 09:15AM	Progyny, Inc. (PGNY) Hit a 52 Week High, Can the Run Continue? (Zacks)
Nov-17-25 08:40AM	Take the Zacks Approach to Beat the Markets: Macy's, United Natural Foods & Monster Beverage in Focus (Zacks)
Nov-14-25 09:45AM	Here's Why Cencora (COR) is a Strong Growth Stock (Zacks)
Nov-13-25 09:40AM	Why Cencora (COR) is a Top Value Stock for the Long-Term (Zacks)
Nov-12-25 12:36AM	The 5 Most Interesting Analyst Questions From Cencora's Q3 Earnings Call (StockStory)
Nov-11-25 04:51AM	Cencora Stock: Is Wall Street Bullish or Bearish? (Barchart)
Nov-07-25 09:50AM	Why Cencora (COR) is a Top Momentum Stock for the Long-Term (Zacks)
Nov-06-25 04:45PM	Cencora makes $1 billion investment in pharma supply chains (FreightWaves)
06:21AM	Cencora to invest $1bn in US pharma distribution network (Pharmaceutical Technology)
12:34AM	COR Q3 Deep Dive: Specialty Expansion and Portfolio Restructuring Drive Strategic Focus (StockStory)
Nov-05-25 09:36PM	Analyst Report: McKesson Corporation (Morningstar Research)
04:00PM	Cencora Inc (COR) Q4 2025 Earnings Call Highlights: Strategic Investments Propel Growth Amid ... (GuruFocus.com)
02:59PM	Analyst Report: Cencora, Inc. (Morningstar Research)
11:54AM	Rigetti Computing to Post Q3 Earnings: What's in Store for the Stock? (Zacks)
10:56AM	COR Q4 Earnings & Revenues Beat Estimates, Gross Margin Improves (Zacks)
09:30AM	Cencora (COR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:40AM	Cencora (COR) Q4 Earnings and Revenues Surpass Estimates (Zacks)
07:00AM	Drug Distributor Cencora to Invest $1 Billion in U.S. Supply Chain (The Wall Street Journal)
06:44AM	Cencora's (NYSE:COR) Q3 Sales Top Estimates (StockStory)
06:39AM	Cencora: Fiscal Q4 Earnings Snapshot (Associated Press Finance)

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments. The U.S. Healthcare Solutions segment is involved in the offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers. The International Healthcare Solutions segment includes businesses that focus on international pharmaceutical wholesale and related service operations, and global commercialization services. The company was founded by Emil P. Martini in 1947 and is headquartered in Conshohocken, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mauch Robert P.	President & CEO	Feb 20 '26	Option Exercise	86.09	3,762	323,871	69,155	Feb 24 04:04 PM
Mauch Robert P.	President & CEO	Feb 20 '26	Sale	358.94	3,762	1,350,332	65,393	Feb 24 04:04 PM
Mauch Robert P.	President & CEO	Feb 18 '26	Sale	359.46	1,333	479,160	65,393	Feb 20 04:00 PM
Mauch Robert P.	Officer	Feb 20 '26	Proposed Sale	358.94	3,762	1,350,332		Feb 20 12:27 PM
Mauch Robert P.	Officer	Feb 18 '26	Proposed Sale	359.46	1,333	479,160		Feb 18 11:03 AM
Mauch Robert P.	President & CEO	Jan 20 '26	Option Exercise	86.09	3,763	323,957	71,822	Jan 22 04:43 PM
Mauch Robert P.	President & CEO	Jan 20 '26	Sale	354.73	5,096	1,807,704	66,726	Jan 22 04:43 PM
Mauch Robert P.	Officer	Jan 20 '26	Proposed Sale	354.73	5,096	1,807,704		Jan 20 11:14 AM
Battaglia Silvana	Executive Vice President	Dec 19 '25	Sale	345.00	1,677	578,565	18,796	Dec 22 04:15 PM
Campbell Elizabeth S	Executive Vice President	Dec 19 '25	Sale	342.10	3,351	1,146,377	23,891	Dec 22 04:15 PM
Mauch Robert P.	President & CEO	Dec 18 '25	Option Exercise	86.09	3,763	323,957	73,155	Dec 22 04:14 PM
Mauch Robert P.	President & CEO	Dec 18 '25	Sale	343.45	5,096	1,750,221	68,059	Dec 22 04:14 PM
Campbell Elizabeth S	Officer	Dec 19 '25	Proposed Sale	342.10	3,351	1,146,377		Dec 19 04:15 PM
Krikorian Lazarus	SVP & Chief Accounting Officer	Dec 17 '25	Sale	343.24	4,031	1,383,580	17,154	Dec 19 04:04 PM
Cleary James F	Chief Financial Officer	Dec 17 '25	Option Exercise	86.09	45,154	3,887,308	180,095	Dec 19 04:03 PM
Battaglia Silvana	Officer	Dec 19 '25	Proposed Sale	345.00	1,677	578,565		Dec 19 11:03 AM
Mauch Robert P.	Officer	Dec 18 '25	Proposed Sale	343.45	5,096	1,750,221		Dec 18 09:48 AM
Krikorian Lazarus	Officer	Dec 17 '25	Proposed Sale	343.24	4,031	1,383,580		Dec 17 03:55 PM
Mauch Robert P.	President & CEO	Nov 18 '25	Option Exercise	86.09	3,763	323,957	70,842	Nov 19 05:09 PM
Mauch Robert P.	President & CEO	Nov 18 '25	Sale	366.64	5,096	1,868,397	65,746	Nov 19 05:09 PM
Mauch Robert P.	Officer	Nov 18 '25	Proposed Sale	366.64	5,096	1,868,397		Nov 18 11:43 AM
COLLIS STEVEN H	Former Officer & Director	Nov 18 '25	Proposed Sale	366.64	31,349	11,493,797		Nov 18 10:40 AM
COLLIS STEVEN H	Former Officer & Director	Nov 06 '25	Proposed Sale	355.25	50,000	17,762,554		Nov 06 04:16 PM
Verma Pawan	EVP, Chief Data & Info Officer	Oct 31 '25	Option Exercise	337.81	8,537	2,883,884	8,551	Nov 04 04:15 PM
Mauch Robert P.	President & CEO	Oct 20 '25	Option Exercise	86.09	3,763	323,957	43,037	Oct 21 04:33 PM
Mauch Robert P.	President & CEO	Oct 20 '25	Sale	326.80	5,097	1,665,700	37,940	Oct 21 04:33 PM
COLLIS STEVEN H	Former Officer & Director	Oct 21 '25	Proposed Sale	326.99	31,350	10,251,105		Oct 21 04:16 PM
Mauch Robert P.	Officer	Oct 20 '25	Proposed Sale	326.80	5,097	1,665,700		Oct 20 09:36 AM
Campbell Elizabeth S	Executive Vice President	Oct 01 '25	Sale	313.28	1,886	590,846	12,824	Oct 03 04:01 PM
Campbell Elizabeth S	Officer	Oct 01 '25	Proposed Sale	313.28	1,886	590,846		Oct 01 10:36 AM
Mauch Robert P.	President & CEO	Sep 18 '25	Option Exercise	86.09	3,763	323,957	44,371	Sep 22 04:16 PM
Mauch Robert P.	President & CEO	Sep 18 '25	Sale	290.00	5,097	1,478,130	39,274	Sep 22 04:16 PM
COLLIS STEVEN H	Executive Chairman	Sep 16 '25	Option Exercise	86.09	29,350	2,526,742	337,263	Sep 18 03:56 PM
COLLIS STEVEN H	Executive Chairman	Sep 16 '25	Sale	289.86	31,350	9,087,142	305,913	Sep 18 03:56 PM
Mauch Robert P.	Officer	Sep 18 '25	Proposed Sale	290.00	5,097	1,478,130		Sep 18 11:54 AM
COLLIS STEVEN H	Director	Sep 16 '25	Proposed Sale	291.55	31,350	9,140,092		Sep 16 10:27 AM
COLLIS STEVEN H	Executive Chairman	Aug 19 '25	Option Exercise	86.09	12,579	1,082,926	322,492	Aug 20 04:08 PM
COLLIS STEVEN H	Executive Chairman	Aug 19 '25	Sale	289.98	14,579	4,227,618	307,913	Aug 20 04:08 PM
Mauch Robert P.	President & CEO	Aug 18 '25	Option Exercise	86.09	3,225	277,640	45,576	Aug 20 04:06 PM
Mauch Robert P.	President & CEO	Aug 18 '25	Sale	293.53	4,968	1,458,257	40,608	Aug 20 04:06 PM
COLLIS STEVEN H	Director	Aug 19 '25	Proposed Sale	289.98	14,579	4,227,618		Aug 19 09:51 AM
Mauch Robert P.	Officer	Aug 18 '25	Proposed Sale	293.53	4,968	1,458,257		Aug 18 11:06 AM
COLLIS STEVEN H	Executive Chairman	Jul 22 '25	Option Exercise	86.09	12,578	1,082,840	324,491	Jul 23 04:30 PM
COLLIS STEVEN H	Executive Chairman	Jul 22 '25	Sale	292.67	14,578	4,266,543	309,913	Jul 23 04:30 PM
Mauch Robert P.	President & CEO	Jul 18 '25	Option Exercise	86.09	3,225	277,640	47,319	Jul 22 04:23 PM
Mauch Robert P.	President & CEO	Jul 18 '25	Sale	294.11	4,968	1,461,138	42,351	Jul 22 04:23 PM
COLLIS STEVEN H	Director	Jul 22 '25	Proposed Sale	292.67	14,578	4,266,543		Jul 22 09:47 AM
Mauch Robert P.	Officer	Jul 18 '25	Proposed Sale	294.11	4,968	1,461,138		Jul 18 11:44 AM
COLLIS STEVEN H	Executive Chairman	Jun 24 '25	Option Exercise	86.09	12,579	1,082,926	326,492	Jun 25 04:03 PM
COLLIS STEVEN H	Executive Chairman	Jun 24 '25	Sale	292.62	14,579	4,266,107	311,913	Jun 25 04:03 PM
COLLIS STEVEN H	Director	Jun 24 '25	Proposed Sale	292.62	14,579	4,266,107		Jun 24 10:21 AM
Battaglia Silvana	Executive Vice President	Jun 18 '25	Sale	297.40	4,077	1,212,520	11,297	Jun 20 04:06 PM
Mauch Robert P.	President & CEO	Jun 18 '25	Option Exercise	86.09	3,225	277,640	49,063	Jun 20 04:04 PM
Mauch Robert P.	President & CEO	Jun 18 '25	Sale	295.30	4,969	1,467,346	44,094	Jun 20 04:04 PM
Lon Greenberg	Board of directors	Jun 18 '25	Proposed Sale	293.20	1,000	293,200		Jun 18 04:40 PM
Battaglia Silvana	Officer	Jun 18 '25	Proposed Sale	297.41	4,077	1,212,520		Jun 18 12:58 PM
Mauch Robert P.	Officer	Jun 18 '25	Proposed Sale	295.30	4,969	1,467,346		Jun 18 09:50 AM
Krikorian Lazarus	SVP & Chief Accounting Officer	May 29 '25	Sale	288.96	3,000	866,881	17,154	Jun 02 04:08 PM
Krikorian Lazarus	Officer	May 29 '25	Proposed Sale	288.96	3,000	866,881		May 29 11:37 AM
Mauch Robert P.	President & CEO	May 19 '25	Option Exercise	86.09	3,225	277,640	50,807	May 21 04:04 PM
Mauch Robert P.	President & CEO	May 19 '25	Sale	291.43	4,969	1,448,116	45,838	May 21 04:04 PM
COLLIS STEVEN H	Executive Chairman	May 20 '25	Option Exercise	86.09	12,578	1,082,840	328,491	May 21 04:00 PM
COLLIS STEVEN H	Executive Chairman	May 20 '25	Sale	293.84	14,578	4,283,600	313,913	May 21 04:00 PM
COLLIS STEVEN H	Director	May 20 '25	Proposed Sale	293.84	14,578	4,283,600		May 20 09:45 AM
Hopfield Jessica	Member of immediate family of	May 19 '25	Proposed Sale	293.24	12,185	3,573,163		May 19 02:29 PM
Mauch Robert P.	Officer	May 19 '25	Proposed Sale	291.43	4,969	1,448,116		May 19 09:51 AM
GREENBERG LON R	Director	May 14 '25	Sale	279.05	3,000	837,150	17,851	May 16 04:23 PM
GREENBERG LON R	Director	May 14 '25	Proposed Sale	279.05	3,000	837,150		May 14 03:53 PM
COLLIS STEVEN H	Executive Chairman	Apr 22 '25	Option Exercise	86.09	12,579	1,082,926	330,492	Apr 23 04:24 PM
COLLIS STEVEN H	Executive Chairman	Apr 22 '25	Sale	281.81	14,579	4,108,508	315,913	Apr 23 04:24 PM
Mauch Robert P.	President & CEO	Apr 21 '25	Option Exercise	86.09	3,225	277,640	52,551	Apr 22 04:06 PM
Mauch Robert P.	President & CEO	Apr 21 '25	Sale	289.33	4,969	1,437,681	47,582	Apr 22 04:06 PM
COLLIS STEVEN H	Director	Apr 22 '25	Proposed Sale	281.81	14,579	4,108,508		Apr 22 09:42 AM
Mauch Robert P.	Officer	Apr 21 '25	Proposed Sale	289.33	4,969	1,437,681		Apr 21 09:48 AM
COLLIS STEVEN H	Executive Chairman	Mar 25 '25	Option Exercise	86.09	12,578	1,082,840	332,491	Mar 26 04:40 PM
COLLIS STEVEN H	Executive Chairman	Mar 25 '25	Sale	269.51	14,578	3,928,917	317,913	Mar 26 04:40 PM
Campbell Elizabeth S	Executive Vice President	Mar 24 '25	Sale	268.28	4,127	1,107,192	14,665	Mar 26 04:38 PM
COLLIS STEVEN H	Director	Mar 25 '25	Proposed Sale	269.51	14,578	3,928,917		Mar 25 10:16 AM
Campbell Elizabeth S	Officer	Mar 24 '25	Proposed Sale	268.28	4,127	1,107,192		Mar 24 10:53 AM
Mauch Robert P.	President & CEO	Mar 18 '25	Option Exercise	86.09	3,226	277,726	54,296	Mar 19 04:38 PM
Mauch Robert P.	President & CEO	Mar 18 '25	Sale	260.93	4,970	1,296,822	49,326	Mar 19 04:38 PM
Mauch Robert P.	Officer	Mar 18 '25	Proposed Sale	260.93	4,970	1,296,822		Mar 18 12:05 PM
Krikorian Lazarus	SVP & Chief Accounting Officer	Mar 10 '25	Sale	260.06	2,000	520,120	20,154	Mar 11 04:07 PM
Krikorian Lazarus	Officer	Mar 10 '25	Proposed Sale	260.06	2,000	520,120		Mar 10 02:09 PM
Mauch Robert P.	President & CEO	Mar 03 '25	Option Exercise	86.09	3,226	277,726	54,296	Mar 04 05:35 PM
Mauch Robert P.	President & CEO	Mar 03 '25	Sale	255.00	4,970	1,267,350	51,070	Mar 04 05:35 PM
Mauch Robert P.	Officer	Mar 03 '25	Proposed Sale	255.00	4,970	1,267,350		Mar 03 03:28 PM
COLLIS STEVEN H	Executive Chairman	Feb 27 '25	Option Exercise	86.09	12,579	1,082,926	332,492	Feb 28 04:05 PM
COLLIS STEVEN H	Executive Chairman	Feb 27 '25	Sale	251.08	14,579	3,660,495	319,913	Feb 28 04:05 PM
COLLIS STEVEN H	Director	Feb 27 '25	Proposed Sale	251.08	14,579	3,660,495		Feb 27 11:26 AM

BLCO

Bausch + Lomb Corp

COR

Cencora Inc

Upgrade your FINVIZ experience